{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:29:32Z","timestamp":1781018972449,"version":"3.54.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Several interleukin (IL)-17 inhibitors have been approved for the treatment of moderate-to-severe plaque psoriasis (PsO). There is still scope for the development of affordable treatments for PsO.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess, in a phase Ia study, the safety, tolerability and pharmacokinetics (PK) of HB0017, a humanized monoclonal antibody that targets IL-17A, in healthy participants and patients with moderate-to-severe plaque PsO; and, in a phase Ib study, to assess the efficacy of HB0017 in patients with moderate-to-severe plaque PsO.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The phase Ia study (NCT04505033) was a randomized double-blind placebo-controlled dose-escalation study in healthy participants. Each cohort of 10 volunteers was randomly assigned to receive either a single dose of HB0017 (50\u2005mg, 150\u2005mg, 300\u2005mg or 450\u2005mg) or the matching placebo at a ratio of 4 : 1. The phase Ib study (NCT05442788) was a randomized double-blind placebo-controlled dose-escalation study in enrolled patients with moderate-to-severe plaque PsO. Each cohort of 10 patients was randomly assigned to receive either multiple doses of HB0017 (150\u2005mg, 300\u2005mg or 450\u2005mg) or the matching placebo at a ratio of 4 : 1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HB0017 demonstrated dose-proportional linear PK and was tolerated across the dose range assessed. In the phase Ia and Ib studies, participants in both the HB0017 and placebo groups experienced treatment-emergent adverse events (69% vs. 87%, 96% vs. 100%, respectively). HB0017 demonstrated clinically meaningful effects in patients with moderate-to-severe plaque PsO. PASI 75 [\u2265 75% improvement in Psoriasis Area and Severity Index (PASI)], PASI 90 (\u2265 90% improvement in PASI) and static Physician Global Assessment (sPGA) 0\/1 (i.e.\u00a0\u2018clear\u2019 or \u2018almost clear\u2019) responses were 100% for the HB0017 300-mg group, with maximal improvements (100% or near 100% reductions from baseline) in PASI score observed at week 12, while the duration of effect was evident up to week 20. There was no clinical response in any participant in the placebo group in the phase Ib study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overall, HB0017 showed acceptable safety and tolerability in both healthy participants and patients with moderate-to-severe plaque PsO. An encouraging signal of efficacy with a longer half-life provides HB0017 with the potential to be added to the currently available range of biologics targeting IL-17A.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad315","type":"journal-article","created":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T17:18:47Z","timestamp":1693761527000},"page":"28-36","source":"Crossref","is-referenced-by-count":8,"title":["Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis"],"prefix":"10.1093","volume":"190","author":[{"given":"Congjun","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Dermatology, the First Affiliated Hospital of Bengbu Medical College , Bengbu City , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Du","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2770-4174","authenticated-orcid":false,"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuizhu","family":"Ge","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyue","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoxiong","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benke","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gege","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the First Affiliated Hospital of Bengbu Medical College , Bengbu City , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the First Affiliated Hospital of Bengbu Medical College , Bengbu City , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoxiao","family":"Qian","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"},{"name":"School of Life Sciences and Human Phenome Institute, Fudan University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Ma","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhan","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmin","family":"Yang","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Shanghai Huaota Biopharmaceutical Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"2024090210030850700_ljad315-B1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2024090210030850700_ljad315-B2","author":"World Health Organization"},{"key":"2024090210030850700_ljad315-B3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2024090210030850700_ljad315-B4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.5694\/mja2.50591","article-title":"Beyond skin deep: addressing comorbidities in psoriasis","volume":"212","author":"Kovitwanichkanont","year":"2020","journal-title":"Med J Aust"},{"key":"2024090210030850700_ljad315-B5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: a systematic review and meta-analysis","volume":"77","author":"Singh","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024090210030850700_ljad315-B6","doi-asserted-by":"crossref","first-page":"715839","DOI":"10.3389\/fimmu.2021.715839","article-title":"Stigmatization in patients with psoriasis: a mini review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"2024090210030850700_ljad315-B7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/11591580-000000000-00000","article-title":"The burden of moderate to severe psoriasis: an overview","volume":"30","author":"Raho","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"2024090210030850700_ljad315-B8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/14737167.2014.933671","article-title":"The economic burden of psoriasis: a systematic literature review","volume":"14","author":"Feldman","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2024090210030850700_ljad315-B9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2217\/imt-2020-0292","article-title":"Immunotherapy in psoriasis","volume":"13","author":"Landeck","year":"2021","journal-title":"Immunotherapy"},{"key":"2024090210030850700_ljad315-B10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin Immunopathol"},{"key":"2024090210030850700_ljad315-B11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/2589977513666210707114520","article-title":"IL-23\/Th17 axis: a potential therapeutic target of psoriasis","volume":"14","author":"Sharma","year":"2022","journal-title":"Curr Drug Res Rev"},{"key":"2024090210030850700_ljad315-B12","doi-asserted-by":"crossref","first-page":"e13403","DOI":"10.1111\/dth.13403","article-title":"Brodalumab: a new way to inhibit IL-17 in psoriasis","volume":"33","author":"Facheris","year":"2020","journal-title":"Dermatol Ther"},{"key":"2024090210030850700_ljad315-B13","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.3390\/ijms22136740","article-title":"From messengers to receptors in psoriasis: the role of IL-17RA in disease and treatment","volume":"22","author":"Vidal","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024090210030850700_ljad315-B14","author":"UCB News"},{"key":"2024090210030850700_ljad315-B15","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"2024090210030850700_ljad315-B16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","article-title":"Anti IL-17 in psoriasis","volume":"15","author":"Ly","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2024090210030850700_ljad315-B17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijbiomac.2022.01.119","article-title":"Structural and functional insights into a novel pre-clinical-stage antibody targeting IL-17A for treatment of autoimmune diseases","volume":"202","author":"Xu","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"2024090210030850700_ljad315-B18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jcph.876","article-title":"Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis","volume":"57","author":"Bruin","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2024090210030850700_ljad315-B19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2024090210030850700_ljad315-B20","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/bcp.15034","article-title":"Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)","volume":"88","author":"Jackson","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2024090210030850700_ljad315-B21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of secukinumab in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2024090210030850700_ljad315-B22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of ixekizumab through 5\u2005years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024090210030850700_ljad315-B23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"2024090210030850700_ljad315-B24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14740338.2020.1730326","article-title":"The safety of brodalumab for the treatment of psoriasis","volume":"19","author":"Iznardo","year":"2020","journal-title":"Expert Opin Drug Saf"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad315\/52186537\/ljad315.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/1\/28\/58992338\/ljad315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/1\/28\/58992338\/ljad315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T12:40:29Z","timestamp":1725280829000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/1\/28\/7260767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,5]]},"published-print":{"date-parts":[[2023,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad315","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,9,5]]}}}